The present invention provides an aminopyrazole compound, or a pharmaceutically acceptable salt thereof or a solvate of the salt, that inhibits Chk1 and is useful in the treatment of cancer.
[EN] CHK1/2 INHIBITORS FOR USE IN THE TREATMENT OF NEUROBLASTOMAS AND/OR SOFT TISSUE SARCOMAS<br/>[FR] UTILISATION D'INHIBITEURS DE CHK1/2 DANS LE TRAITEMENT DE NEUROBLASTOMES ET/OU DE SARCOMES DES TISSUS MOUS
申请人:LILLY CO ELI
公开号:WO2017015124A1
公开(公告)日:2017-01-26
The present invention provides 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-lH- pyrazol-3-ylamino)pyrazine~2~carbonitrile and pharmaceutically acceptable salts and solvates thereof, that is capable of inhibiting CHK1 and is useful in the treatment of neuroblastomas and/or soft tissue sarcomas.
5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
申请人:Eli Lilly and Company
公开号:US08314108B2
公开(公告)日:2012-11-20
The present invention provides an aminopyrazole compound, more particularly,
or a pharmaceutically acceptable salt thereof or a solvate of the salt, that inhibits Chk1 and is useful in the treatment of cancer.
CHK1/2 inhibitors and irinotecan for use in the treatment of rhabdomyosarcoma
申请人:Eli Lilly and Company
公开号:US11123326B2
公开(公告)日:2021-09-21
The present invention provides 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine˜2˜carbonitrile and pharmaceutically acceptable salts and solvates thereof that is capable of inhibiting CHK1 and is useful in the treatment of neuroblastomas and/or soft tissue sarcomas.